Ionis Pharmaceuticals, Inc. (IONS) Earnings History
Annual and quarterly earnings data from 1991 to 2025
Loading earnings history...
IONS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
IONS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 98.3% | -40.5% | -40.4% |
| 2024 | 98.4% | -67.4% | -64.4% |
| 2023 | 98.8% | -44.9% | -46.5% |
| 2022 | 97.6% | -69.8% | -45.9% |
| 2021 | 98.7% | -3.7% | -3.5% |
Download Data
Export IONS earnings history in CSV or JSON format
Free sign-in required to download data
Ionis Pharmaceuticals, Inc. (IONS) Earnings Overview
As of May 8, 2026, Ionis Pharmaceuticals, Inc. (IONS) reported trailing twelve-month net income of -$327M, reflecting +21.7% year-over-year growth. The company earned $-1.98 per diluted share over the past four quarters, with a net profit margin of -40.4%.
Looking at the long-term picture, IONS's historical earnings data spans multiple years. The company achieved its highest annual net income of $278M in fiscal 2019.
Ionis Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ALNY ($577M net income, 8.4% margin), SRPT ($65M net income, -32.5% margin), BMRN ($269M net income, 10.8% margin), IONS has room to improve margins relative to the peer group. Compare IONS vs ALNY →
IONS Earnings vs Peers
Earnings metrics vs comparable public companies
IONS Historical Earnings Data (1991–2025)
35 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$381M | +16.1% | -$382M | $-2.38 | -40.4% | -40.5% |
| 2024 | -$454M | -23.9% | -$475M | $-3.04 | -64.4% | -67.4% |
| 2023 | -$366M | -35.8% | -$354M | $-2.56 | -46.5% | -44.9% |
| 2022 | -$270M | -843.2% | -$410M | $-1.90 | -45.9% | -69.8% |
| 2021 | -$29M | +93.6% | -$30M | $-0.20 | -3.5% | -3.7% |
| 2020 | -$444M | -259.7% | -$172M | $-3.18 | -60.9% | -23.6% |
| 2019 | $278M | +1.6% | $366M | $2.06 | 24.8% | 32.6% |
| 2018 | $274M | +79015.9% | -$61M | $2.04 | 45.6% | -10.2% |
| 2017 | $346,000 | +100.6% | $31M | $-0.05 | 0.1% | 6.0% |
| 2016 | -$60M | +31.6% | -$20M | $-0.72 | -16.2% | -5.4% |
Full IONS Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See IONS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IONS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IONS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIONS — Frequently Asked Questions
Quick answers to the most common questions about buying IONS stock.
Is IONS growing earnings?
IONS EPS is $-1.98, with earnings growth accelerating to +21.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-327M.
What are IONS's profit margins?
Ionis Pharmaceuticals, Inc. net margin is -40.4%, with operating margin at -40.5%. Below-average margins reflect competitive or cost pressures.
How consistent are IONS's earnings?
IONS earnings data spans 1991-2025. The accelerating earnings trend is +21.7% YoY. Historical data enables comparison across business cycles.